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PREDICTORS OF LOST TO FOLLOW UP AMONG PATIENTS WITH 
ISCHEMIC RETINOPATHIES: A RETROSPECTIVE COHORT STUDY 
SINJIN CHARLES SWARTZ 
ABSTRACT 
Purpose: Retinal and choroidal ischemic retinopathies such as retinal-vein occlusion 
(RVO), diabetic retinopathy (DR), and age-related macular degeneration (AMD) are 
ocular diseases caused by abnormal changes in the microvasculature. The ischemia can 
lead to macular edema or neovascularization, which can affect vision. Intravitreal 
injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) can help to reduce 
macular edema and improve visual acuity. Lost to follow-up (LTFU) after anti-VEGF 
injections increases the risk of vision loss in patients with RVO, DR, and AMD. 
 
Methods: Patients scheduled for an IVI of anti-VEGF between September 2009 and 
September 2019 with either RVO, DR, or AMD were included in the analysis. LTFU was 
defined as missing an appointment without another evaluation for at least one interval 
exceeding 180 days. All patients were seen by a single provider at an urban, hospital-
based, single-site retina practice in Boston, MA. 
 
Results:  
Among the 698 patients (mean [SD] age, 70.23 [14.2] years; 373 [53.4%] female) 
identified as receiving an IVI, 121 (17.3%) were LTFU. Age was not found to be 
statistically different between the LTFU and not LTFU groups (mean difference, -1.67; 
 
 vi
95% CI, -4.66–1.32; P=.27). Odds of LTFU was lower among patients with AMD (odds 
ratio [OR], 0.57; 95% CI, 0.36-0.92; P=.02). Odds of LTFU was greater among patients 
with Medicaid insurance (OR, 2.31; 95% CI, 1.22-4.33; P=.01), compared with patients 
with Medicare insurance. A trend towards higher risk of LTFU was seen in patients with 
DR (OR, 1.42; 95% CI, 0.94-2.15; P=.09) and a toward lower risk in patients with two or 
more eye diseases (OR, 0.53; 95% CI, 0.24-1.15; P=.10). Medicaid insurance was the 
only significant (P=.02) independent risk factor of LTFU in the multivariate regression.   
 
Conclusion: We found a high rate of LTFU after anti-VEGF injections among patients 
with RVO, DR, AMD, and identified risk and protective factors associated with LTFU 
among this population. Although our results may not be generalizable, data on LTFU in a 
clinical practice setting are needed to understand the scope of the problem so that 
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Eye Anatomy and Physiology 
 The eye is one of the most complex organs of the human body and has three 
distinct layers. The outer region consists of the cornea and sclera (Figure 1). The cornea 
provides about two-thirds of the total refractory power, transmits light to the lens, and 
protects the underlying layers against infection and structural damage. The sclera forms a 
connective tissue coat that protects the eye from internal and external forces and helps the 
eye to maintain its shape. The conjunctiva, a transparent mucous membrane, covers the 
visible part of the sclera and underside of the eyelids. The middle layer of the eye is 
composed of the iris, the ciliary body, and the choroid. The iris controls the size of the 
pupil, which changes the amount of light that enters the eye. The ciliary body changes the 
shape of the lens, providing the final one-third of the dioptric power, and focusing the 
eyeball. This accommodation process lets the eye adapt to any distance of view (Lazar & 
Baritz, 2020). The choroid is a vascular layer that provides oxygen and nutrients to the 
outer retinal layers. The innermost layer is the retina and contains the photoreceptors that 




Figure 1. Anatomy of the Eye 
A horizontal section through the eye showing the three main layers: sclera, uvea, and 
retina. The space within the eye can be subdivided into three compartments: anterior 




 The choroid is a highly vascular tissue, and per unit weight, it has the highest 
blood flow in the body (Tan et al., 2017). Its location between the sclera and retina allows 
it to supply the outer retina with nutrients and maintain the temperature and volume of 
the eye (Figure 2) (Ehrlich et al., 2010). The choroid is comprised of blood vessels, 
melanocytes, fibroblasts, resident immunocompetent cells, and supporting collagenous 
and elastic connective tissue (Nickla & Wallman, 2010). Its circulation is controlled 
mainly by sympathetic innervation and is not considered to be autoregulated (Luo et al., 
2015). Autoregulation is a capacity to maintain a relatively constant level of blood flow 
in the presence of changes in ocular perfusion pressure and varied metabolic demand. 
The lack of autoregulation makes the choroid more dependent on the ocular perfusion 
 
3 
pressure (Ehrlich et al., 2010). Impairment of the flow of oxygen from the choroid to the 
retina may cause degenerative changes, like AMD and neovascularization (Nickla & 
Wallman, 2010). 
 
Figure 2. Posterior Eye 
Photomicrograph of the three tunics in the back of the primate eye. The choroid’s 
position between the retina and sclera is visible. Image from Nickla & Wallman, 2010. 
 
Retina 
 The overall organization of the neural retina is complex, with as many as ten 
anatomical layers having been described (Figure 3). The basic organization, however, is 
relatively straightforward when subdivided into three layers: an outer layer of 
photoreceptors, a middle layer of bipolar neurons, and an inner layer of ganglion cells 
that collect visual signals and carry them to the optic nerve (Carlson, 2019). The 
horizontal and amacrine cells are oriented perpendicularly and function to connect and 
integrate the various vertical pathways of the three-neuron chain. Finally, the Müllerian 
cells extend through almost the entire thickness of the neural retina to serve several 
functions similar to those of glial cells: to maintain a stable extracellular environment by 
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regulating the ionic environment, the balance of neurotransmitters, storing energy 
sources, and serving as insulation and mechanical support for neurons (Carlson, 2019). 
 
Figure 3. Cells and Layers of the Retina 
Light travels through the various neural layers to reach the photoreceptors. Inner limiting 
membrane (ILM), nerve fiber layer (NFL), inner plexiform layer (IPL), inner nuclear 
layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), outer limiting 
membrane (OLM), rods and cones layer (R&CL), retinal pigmented epithelium (PE). 
Image from Willoughby et al., 2010. 
 
 Another significant component of the retina is the retinal pigment epithelium 
(RPE), a monolayer of cells between the neurosensory retina and the choroid (Ponnalagu 
et al., 2017). The cuboidal cells of the RPE have the quality of being heavily pigmented. 
These pigment granules absorb scattered light, and by doing so, improve the optical 
qualities of the eye and protect the sensitive cells of the neural retina from photooxidative 
stress (Carlson, 2019). Additionally, the RPE is the main component of the outer blood-
retinal barrier (BRB). The outer BRB is located at the tight junctions between the apical 
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lateral membranes of the RPE cells. Its integrity is fundamentally essential for the health 
and wellbeing of the inner retina (Soubrane & Coscas, 2013). 
 The photoreceptors function in the process of visual transduction. These cells 
transform light signals to nerve impulses that are eventually transmitted from the optic 
nerve to the brain, forming an image. There are two types of photoreceptor cells: rods and 
cones. The rod cells function well in low-light conditions, and the cone cells are for color 
vision. The macula is the small part of the retina responsible for central vision and 
contains a very high density of cone cells, thereby providing high visual acuity (Figure 4) 
(Stone et al., 2020). Within the macula is an area known as the fovea, which contains in 
its center the foveal pit. This pit is devoid of rod photoreceptors and secondary and 
tertiary neurons, allowing light to directly stimulate the tightly packed cones with 
minimum scatter from overlying tissues (Kolb et al., 1995). This organizational structure 
gives maximum visual acuity for central vision. 
 
Figure 4. Fundus 
The ocular fundus is the concave surface lining the inside of the eyeball opposite of the 
lens. The macula, fovea, and optic disk have been labeled. The retinal vasculature as well 




 The retina is considered one of the highest oxygen-consuming tissues of the body, 
exceeding that of even the brain on a per gram basis (Ames et al., 1992). The retina has a 
dual vascular supply and receives its nutrients from both the choroidal and retinal blood 
flow (Treuting et al., 2012). Blood supply to the outer retina, mainly the photoreceptor 
cells, comes from choroidal capillaries that originate from ciliary arteries, whose source 
is the ophthalmic artery. The choroidal circulation is characterized by a high flow rate 
and of low oxygen extraction (Linsenmeier & Padnick-Silver, 2000). Blood supply to the 
inner retina is provided by the central retinal artery, also a branch of the ophthalmic 
artery (Wong-Riley, 2010). Retinal blood flow is characterized by a low flow rate and a 
high level of oxygen extraction (Linsenmeier & Padnick-Silver, 2000). Unlike choroidal 
blood flow, retinal blood flow is autoregulated. Ocular blood flow regulation 
compensates for changes in ocular activity, keeping the relative constant ocular 
temperature and retinal perfusion pressure (Luo et al., 2015). Autoregulation is achieved 
through the interaction of myogenic and metabolic mechanisms through the release of 
vasoactive substances by the vascular endothelium and retinal tissue surrounding the 
arteriolar wall (Pournaras et al., 2008). 
Retinal-Vein Occlusion 
 Retinal-Vein Occlusions (RVO), the second most common retinal vascular 
disease after diabetic retinopathy, is one of the common causes of visual morbidity and 
blindness in the elderly population (Sinawat et al., 2017). It can result in significant 
visual loss from complications like macular edema, retinal and iris neovascularization, 
and vitreous hemorrhage (Tan et al., 2019). Patients with RVO typically present with 
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sudden, unilateral, painless loss of vision, with the degree of vision loss mostly dependent 
on the extent of the retinal involvement and perfusion status of the macula. There are two 
distinct types of RVO classified according to the site of occlusion. In branch retinal-vein 
occlusion (BRVO), the occlusion is typically at an arteriovenous intersection. In central 
retinal-vein occlusion (CRVO), the occlusion is at or proximal to the lamina cribrosa of 
the optic nerve, where the central retinal vein exits the eye (Figure 5) (Hayreh, 2005). 
Both BRVO and CRVO are further divided into the categories of perfused (nonischemic) 
and nonperfused (ischemic), each having implications for prognosis and treatment. 
 
Figure 5. Nonperfused Central Retinal-Vein Occlusion in Left Eye 
A fundus photograph (Panel A) shows scattered retinal hemorrhages (white arrows), 
cotton-wool spots (black arrows), optic-disk edema and hyperemia, and venous dilatation 
and tortuosity (yellow arrow), and a fluorescein angiogram (Panel B) reveals areas of 
capillary nonperfusion (white arrows) and disk leakage (yellow arrow). Optical-
coherence tomographic scans (horizontal scan in Panel C and vertical scan in Panel D) 
show marked retinal thickening (white arrows) and edema (yellow arrows). N→T 
denotes a nasal-to-temporal cut of the retinal scan, and I→S an inferior-to-superior cut. 




 Studies find that RVO has a prevalence of approximately 1-2% in individuals 40 
years of age and older. A meta-analysis of 15 studies from the United States, Europe, 
Asia, and Australia calculated that RVOs have an age- and sex-standardized prevalence 
of 5.20 per 1,000 for any RVO, 4.42 per 1,000 for BRVOs, and 0.80 per 1,000 for 
CRVOs (Rogers et al., 2010). Worldwide, an estimated 16.4 million adults are affected 
by RVOs, with 2.5 million affected by CRVOs and 13.9 million affected by BRVOs (Ho 
et al., 2016). These statistics have also been supported by population-based 
epidemiological studies of RVO with a long follow-up period. 
 The Blue Mountains Eye Study aimed to determine the prevalence and 
associations of RVO in a defined older Australian population (Mitchell et al., 1996). 
Their study sample consisted of 3,654 participants aged 49 years of age or older and 
represented 88% of the permanent residents from an area west of Sydney, Australia. 
Participants all underwent a detailed eye exam, and the diagnosis of RVO was made 
clinically and from photographic grading. The study found that signs of RVO were found 
in 59 participants (1.6%; 95% confidence interval, 1.3-1.9%) with no significant sex 
differences in prevalence (Mitchell et al., 1996). There was, however, increasing 
prevalence in each ten-year age category above 60 years of age. Of the patients with 
RVO, around 70% had BRVO, and 25% had CRVO, with the remaining being diagnosed 
with hemiretinal-vein occlusion. Consistent with the amount of occlusion present in each 
condition, visual acuity was most affected in people with CRVO, with a visual acuity of 
20/200 or less in 60% compared to 14% among individuals with CRVO and BRVO, 
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respectively (Mitchell et al., 1996). In this cohort, RVO was the fifth most frequent cause 
of unilateral blindness and found significantly associated with glaucoma, hypertension, 
stroke, and angina. 
 Similar to The Blue Mountains Eye Study, The Beaver Dam Eye Study also 
sought to describe the incidence of RVO and its associated risk factors. Four thousand 
sixty-eight participants from Beaver Dam, Wisconsin, aged 43 to 84 years of age, were 
evaluated at baseline for an RVO and then evaluated again at three consecutive 5-year 
follow-up visits. The researchers found that the 15-year cumulative incidences of BRVO 
and CRVO were 1.8% to 0.5%, respectively (Klein et al., 2008). Significant increases in 
the odds ratio (OR) of developing either BRVO or CRVO were found for glaucoma 
(OR= 3.17), barbiturate use (OR=5.30), and baseline age (OR=1.70) (Table 1). The 
researchers concluded that RVO is not infrequent in the population, especially after age 












Table 1. Multivariate Relations of Risk Factors to the 15-Year Cumulative 
Incidence of Retinal Vein Occlusion in the Beaver Dam Study, 1988 to 2005 
The odds ratios (OR) and corresponding p-values for different risk factors contributing to 
BRVO, CRVO, and BRVO or CRVO. Table from Klein et al., 2008 
 
 In young patients, however, CRVO is more commonly associated with 
hematological abnormalities or pro-coagulant conditions (Ho et al., 2016). These 
conditions include, but are not limited to, anemia, polycythemia, leukemia, multiple 
myeloma, abnormal platelet function, and reduced anti-thrombin III (Tan et al., 2019). 
Nalcaci et al. (2019) retrospectively studied the clinical records of patients with RVO 
under the age of 50 to identify etiological factors. Of the 40 patients that were analyzed, 
15 (37.5%) patients had hyperhomocysteinemia, 16 (40%) patients had either diabetes or 
hypertension, and 11 (27.5%) patients had a methylenetetrahydrofolate reductase gene 
mutation (Nalcaci et al., 2019). The researchers concluded that etiological factors that 
might result in RVO in young individuals should be investigated in further detail to 
develop targeted therapies.  
 Younger patients may also have a different disease course than older patients. 
Rothman et al. (2019) compared the presentation and outcomes of patients younger than 
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50 years of age to patients aged 50 years and older with CRVO. This single-center 
retrospective study included patients presenting between January 2009 and July 2016. In 
total, there were 36 patients younger than 50 years and 233 patients greater than or equal 
to 50 years at the time of CRVO onset included in the analysis (Rothman et al., 2019). At 
presentation, younger patients had better visual acuity and a lower incidence of cystoid 
macular edema. Younger patients also had better final acuities and received fewer total 
intravitreal injections (IVI) than older patients (Rothman et al., 2019). 
Pathophysiology 
 The pathogenesis of BRVO is thought to involve both retinal vein compression 
and damage to the vessel wall, possibly leading to thrombus formation (Mitry et al., 
2013). As stated previously, BRVOs are thought to occur at sites where retinal arterioles 
cross retinal veins. Histopathological studies support this hypothesis by showing 
arteriolar wall thickening, vein compression, and altered blood flow resulted in 
thrombosis and vein occlusion (Frangieh et al., 1982). Once the occlusion occurs, 
increased vascular pressure behind the occlusion may lead to leakage of both fluid and 
small molecules across the vascular wall and into the surrounding retinal tissue, resulting 
in localized edema.  
 At the biochemical level, there are also changes taking place. Endothelial damage 
to the affected vein may induce low-grade chronic inflammation of the retinal 
microvasculature and upregulation of inflammatory mediators (Ehlers & Fekrat, 2011). 
These mediators include prostaglandins, leukotrienes, intercellular adhesion molecule-1, 
tumor necrosis factor-alpha, and VEGF (Koss et al., 2012). Increased VEGF production 
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causes local inflammation and increases vascular permeability, leading to macular edema. 
Retinal ischemia resulting from RVO may result in neovascularization, either in the 
anterior segment or in the retina. Neovascularization of the iris or angles may progress to 
neovascular glaucoma, while neovascularization in the retina may progress to retinal 
detachment or vitreous hemorrhage (McIntosh et al., 2010). Vinores et al. (1997) stained 
for VEGF and found that it was elevated in the retina and iris of patients with ischemic 
retinopathies such as DR and RVO. They found that VEGF was primarily localized 
around retinal neurons and retinal pigmented epithelial cells. The researchers also noted 
that in addition to VEGF’s role in inducing neovascularization, it might contribute to the 
BRB breakdown seen in a variety of ocular disorders (Vinores et al., 1997). 
 Ozaki et al. (1997) studied if VEGF alone was sufficient to cause retinal 
neovascularization using an animal model. Researchers implanted pellets containing 
either human recombinant VEGF, control pellets containing vehicle only, or control 
pellets containing human serum albumin into the vitreous cavity of rabbits and primates. 
The pellets would slowly release their contents over a few weeks, and the eyes would be 
examined by indirect ophthalmoscopy, fundus photography, and fluorescein angiography. 
Finally, the animals would be sacrificed at different time points for immunocytochemical 
evaluations to be carried out (Ozaki et al., 1997). Researchers noted interesting results 
with the rabbits. After seven days, rabbits exposed to 30 µg VEGF had retinal blood 
vessels that were dilated and tortuous, and between days 14 and 21, retinal 
neovascularization was noted in all eyes. Fluorescein angiography revealed profuse 
leakage of dye from neovascular vessels. Eyes implanted with either of the two control 
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pellets did not experience retinal vascular abnormalities (Ozaki et al., 1997). Implantation 
of pellets containing 100µg of VEGF into the vitreous cavity of primates resulted in iris 
neovascularization, retinal vascular dilation, and tortuosity similar to that seen in humans 
with ischemic retinopathies. Immunohistochemical staining for serum albumin showed a 
widespread severe breakdown of the BRB, and histology showed dilated thin-walled 
retinal vessels (Ozaki et al., 1997). These findings suggest that sustained intravitreal 
release of VEGF causes widespread retinal vascular dilation and breakdown of the BRB. 
The researchers concluded that VEGF antagonists might provide a new therapy for 
patients with ischemic retinopathies and macular edema. 
Diabetic Retinopathy 
 Diabetic retinopathy (DR) is a common and specific microvascular complication 
of diabetes and remains the leading cause of preventable blindness in working-aged 
people (Cheung et al., 2010). Patients with DR are 25 times more likely to become blind 
than non-diabetics, and have impaired quality of life, reduced physical, emotional, and 
social well-being, and use more healthcare resources (Singh et al., 2008) (Fenwick et al., 
2011). Without treatment, DR progresses from mild non-proliferative DR (NPDR) to 
moderate and severe NPDR before the occurrence of proliferative DR (PDR), in which 
there is a growth of abnormal new retinal blood vessels (Wong et al., 2016). In its non-
proliferative stages, DR is mostly asymptomatic but may cause significant and disabling 
vision loss at the severe NPDR and PDR stages (Fenwick et al., 2011). NPDR is 
characterized by the presence of microaneurysms, dot and blot hemorrhages, hard 
exudates, cotton wool spots, vascular changes, intravitreal microvascular abnormalities, 
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or retinal edema (Figure 6) (Singh et al., 2008). Neovascularization in PDR usually 
occurs on the optic disk and at the junction of nonperfused retinal vessels and perfused 
vessels that are leaking (Antonetti et al., 2012). Concurrently, at any stage of retinopathy, 
with exudation and edema at the macula, patients may also develop diabetic macular 
edema (DME) (Wong et al., 2016). DME is the most common cause of vision loss in 
patients with DR (Wang & Lo, 2018). 
 
Figure 6. Clinical Features of Diabetic Retinopathy 
A fundus photograph (Panel A) shows the left eye of a 57-year-old man with 20/200 
visual acuity with signs of hypertension and PDR with macular edema (the region of 
macular edema is indicated by the bracket). Notable features include arteriolar narrowing 
(AN), nerve-fiber hemorrhage (NFH), hard exudates (HE), cotton-wool spots (CWS), 
venous beading (VB), and preretinal hemorrhage (PRH). Optical coherence tomography 
(Panel B) with a horizontal scan through the central fovea (corresponding to the 
horizontal line in Panel A) reveals marked thickening and edema of the macula with cysts 
(C) and subretinal fluid (SRF). Image from Antonetti et al., 2012. 
 
Epidemiology 
 The number of Americans 40 years of age or older with DR is estimated to reach 
16 million by 2050, with vision-threatening diabetic retinopathy affecting an estimated 
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3.4 million of them (Hendrick et al., 2015). Epidemiological studies in the field of 
ophthalmology have provided detailed long-term longitudinal data on the prevalence of 
DR and DME in populations with type 1 diabetes mellitus (T1DM) or type 2 diabetes 
mellitus (T2DM).  
 The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) was a 
population-based study in Southern Wisconsin that studied the prevalence and incidence 
of DR. They stratified their analysis to analyze subjects when age at diagnosis was less 
than or over 30 years of age. In the younger-onset group, the 996 insulin-taking subjects 
were found to have a prevalence of DR that varied from 17% to 97.5% in persons with 
diabetes for less than five years and 15 or more years, respectively (Klein et al., 1984). 
Their Cox regression model found that for persons with diabetes less than ten years in 
duration, the severity of retinopathy was related to being older at first examination, 
longer duration of diabetes, and higher levels of glycosylated hemoglobin. For 
individuals with diabetes longer than ten years, the severity of retinopathy was not only 
related to the factors mentioned above, but also included higher diastolic blood pressure, 
male sex, and the presence of proteinuria (Klein et al., 1984). In the older-onset group, 
1,370 subjects were found to have a prevalence of DR that varied from 28.8% in persons 
who had diabetes for less than five years to 77.8% in persons who had diabetes for 15 or 
more years. Their regression model related the severity of retinopathy to factors such as 
the use of insulin, higher systolic BP, higher glycosylated hemoglobin levels, and 
younger age at diagnosis (Klein et al., 1984). These two analyses reveal that the early 
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onset of diabetes has a poorer prognosis and supports the need for early screening and 
treatment. 
 Two and a half decades later, WESDR examined the cumulative progression and 
regression of DR and its relation to various risk factors. Klein et al. (2008) analyzed 955 
individuals that met specific inclusion criteria: T1DM, diagnosed before age 30, 
participated in a baseline examination in 1980-1982, and made least 1 of 4 (4-,10-,14-, 
and 25-year) follow-up examinations. The 25-year cumulative rate of DR progression 
was 83%, progression to PDR was 42%, and the improvement of DR was 18% (Klein et 
al., 2008). The results show that a great majority of study subjects had their DR worsen 
compared to the small number that saw an improvement in their disease. The researchers 
also noted that there was a lower prevalence of PDR in individuals diagnosed more 
recently, but that had a similar duration of diabetes, which possibly reflects the 
improvements in care throughout the study. 
Pathophysiology 
 The retinal dysfunction associated with diabetes may be viewed as a change in the 
retinal neurovascular unit, referring to the physical and biochemical relationship among 
neurons, glia, and specialized vasculature and the close interdependency of these tissues 
(Figure 7) (Antonetti et al., 2012). Pericytes are a part of this neurovascular unit and are 
associated mainly with the stabilization and hemodynamic processes of blood vessels 
(Bergers & Song, 2005). Pericytes are found wrapped around endothelial cells and can 
produce vasoconstriction and vasodilation within capillary beds to regulate vascular 
diameter and capillary blood flow (Rucker et al., 2000). Pericyte density is higher in 
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retinal than in other capillaries, reflecting a particularly important function at this 
location, and their loss is the earliest morphological sign of retinal vascular abnormalities 
in diabetes (Sims, 1986) (Cogan et al., 1961). Geraldes et al. (2009) found that 
hyperglycemia induces expression of protein kinase C–delta, which upregulates the SRC-
homology-2 domain, containing tyrosine phosphatase-1. This phosphatase inhibits PDGF 
signaling through the protein kinase B survival pathway, contributing to pericyte death 
and vascular derangement. These findings underscore the cell-to-cell communication 
necessary for proper retinal function and maintenance of the BRB (Geraldes et al., 2009).   
 
Figure 7. Disruption of the Neurovascular Unit of the Retina by Diabetes 
Panel A shows the neurovascular unit in the retina. Pericytes and glial cells, including 
astrocytes, promote formation of the BRB in the vasculature, helping to create the 
environment for proper neuronal function. Panel B shows how healthy cellular 
communication is altered in diabetes. A reduced amount of PDGF and pericyte loss 
allows the vasculature to leak blood, which leads to retinal hemorrhaging. Image from 
Antonetti et al., 2012.  
 
 Using a mouse model, Enge et al. (2002) found a strong inverse correlation 
between pericyte density and the formation of a range of retinal microvasculature 
abnormalities. Researchers found that genetic ablation of platelet-derived growth factor-
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beta (PDGF) causes pericyte loss and a phenotype that resembles DR, with increased 
vascular damage and angiogenesis (Enge et al., 2002). They also noted that proliferative 
retinopathy invariably developed when pericyte density was less than 50% of normal. 
They concluded that a reduction in pericyte density was sufficient to cause retinopathy in 
mice and maybe a causal pathogenic event in human DR (Enge et al., 2002). 
  DME, defined as a retinal thickening involving or approaching the center of the 
macula, represents the most common cause of vision loss in patients affected by diabetes 
(Bandello et al., 2017). DME occurs after the breakdown of the BRB from the leakage of 
dilated hyperpermeable capillaries and microaneurysms (Ciulla et al., 2003). The 
prevalence of DME in patients with DR is between 2.7% to 11%, and it depends on the 
type of diabetes and the duration of the disease, but for both T1DM and T2DM after 25-
years duration, it approximates 30% (Browning et al., 2018). 
Age-Related Macular Degeneration 
 AMD is an acquired disease of the macula characterized by progressive visual 
impairment due to late-onset neurodegeneration of the photoreceptor-RPE complex (Al-
Zamil & Yassin, 2017). AMD is a major cause of central vision loss in the developed 
world, affecting 10% of people older than 65 years and more than 25% of people older 
than 75 years (Smith et al., 2001). Approximately 11 million individuals are affected with 
AMD in the United states alone, with a global prevalence of 170 million (Pennington & 
DeAngelis, 2016). Advanced stages of AMD, choroidal neovascularization (CNV), and 
geographic atrophy of RPE, which are usually associated with marked loss of central 
vision, are estimated to affect more than 1.75 million individuals in the United States 
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(Bressler, 2004). Irreversible central vision loss is highly incapacitating in multiple 
physical, social, and emotional areas of patients’ lives as well as is leading to increased 
health resource utilization and high societal cost burden (Cruess et al., 2008). Researchers 
indicate that based on the predicted aging of the United States population, the prevalence 
of AMD is projected to increase to almost 3 million individuals in less than 20 years 
(Bressler, 2004).  
 AMD can be divided into two broad clinical categories depending on whether 
there is a presence of abnormal neovascularization: wet (synonymous with exudative or 
neovascular) and dry AMD (Cook et al., 2008). Dry AMD can then be subdivided into 
three stages: early, intermediate, and advanced. The early stage of dry AMD is defined by 
non-exudative retinal changes characterized by small black hyperpigmented dots, tiny 
atrophic spots, and small hard drusen (<63µm), which are proteinaceous collections at the 
level of the RPE (Rosenbaum, 2012). A patient’s visual acuity is mostly unaffected at this 
point. Hard drusen may enlarge to intermediate size drusen (63-124µm), which may 
progress to soft drusen and merge to still larger ones (≥125µm) (Algvere et al., 2016). 
Intermediate dry AMD displays more hyperpigmentation and large or confluent soft 
drusen, which begin to affect visual acuity. There is a high risk for the transition from 
intermediate AMD that displays bilateral large and confluent drusen to advanced dry 
AMD (AREDS Report No. 8, 2001). Advanced dry AMD is defined by geographic 
atrophy with large areas of RPE damage. Although dry AMD accounts for the majority of 
all diagnosed cases, wet AMD is responsible for the majority of the severe vision loss, 
and it usually occurs over weeks to months (Gheorghe et al., 2015). Wet AMD, also 
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known as neovascular AMD (nAMD), is characterized by the formation of retinal edema, 
newly formed vessels, and hemorrhage. There is, generally, a severe visual loss at these 
stages (Algvere et al., 2016). In addition to drusen and atrophy seen in dry AMD, wet 
AMD is defined by the presence of edema and hemorrhage within or below the retina or 
RPE (Mehta, 2015). 
Epidemiology 
 Wong et al. (2014) estimated the number of individuals affected by AMD 
globally. Their meta-analysis revealed that, within an age range of 45-85 years, AMD had 
a prevalence of 8.69%, with early-stage accounting for 8.01% and late-stage accounting 
for 0.37% (Wong et al., 2014). Their research revealed regional differences as well. 
AMD was more common in populations of European ancestry (12.3%) than of Asian 
ancestry (7.4%) and was markedly less common in populations of African ancestry than 
in populations of European ancestry. Finally, men and women did not differ significantly 
in the prevalence of AMD. The research team also stratified late-stage AMD into signs of 
geographic atrophy and neovascularization. Their results indicate that geographic atrophy 
was more common among Europeans (1.11%) than among Africans (0.14%), Asians 
(0.21%), and Hispanics (0.16%), whereas neovascularization did not differ between 
various ethnic groups (Wong et al., 2014). These data on AMD prevalence varying by 
ethnicity and racial group support the notion on the role of genetic variants, 
environmental exposures, and their interplay in AMD susceptibility will likely vary by 
ethnicity as well (Pennington & DeAngelis, 2016). The association of a higher prevalence 
of AMD with older age was not linear but showed a more pronounced increase beyond 
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the age of 75 years in all ethnicities examined (Jonas et al., 2017). It held in particular for 
the late stage of AMD, especially in individuals of European descent, suggesting a 
nonlinear relationship of the prevalence of AMD with age. 
 The prevalence of AMD in the U.S. is anticipated to increase to 22 million by the 
year 2050, with the global prevalence projected to reach 288 million in the year 2040 
(Wong et al., 2014). In the U.S., the prevalence of AMD is similar to that of all invasive 
cancers combined and more than double the prevalence of Alzheimer’s Disease 
(Pennington & DeAngelis, 2016). This high prevalence leads to an annual $4.6 billion 
direct healthcare cost due to AMD in the U.S. As the aging population increases, this 
expenditure will increase proportionately. 
Pathophysiology  
 The cause of the disease is unknown, and genetic, nutritional, hemodynamic, 
degenerative, and phototoxic factors remain under active investigation (D’Amico, 1994). 
AMD may develop clinically once an accumulation of risk factors exceeds the disease 
threshold, based on an individual’s repair and regenerative capabilities (Khandhadia et 
al., 2012). The most frequent manifestation of AMD is drusen (Figure 8). These lesions 
are visible as pale-yellow spots that may occur individually or in clusters throughout the 
macula (Green et al., 1985). One model for the development of nAMD suggests that the 
accumulation of drusen disrupts the connection between the RPE and the choroidal blood 
supply, thereby inducing hypoxia. Hypoxia, in turn, induces the expression of VEGF and 
other pro-angiogenic factors to promote the formation of new vessels. A vicious cycle 
may develop, where VEGF production increases effusion, retinal detachment, and edema, 
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further increasing hypoxia and VEGF production (Stefánsson et al., 2011). This model 
does not fully capture the complete mechanism, however, as extensive data support roles 
for local inflammation, complement activation, oxidative stress, and lipid homeostasis in 
the pathogenesis of AMD (Gemenetzi & Lotery, 2014). 
 
Figure 8. Age-Related Macular Degeneration 
Fundus photographs from participants in the Age-Related Eye Disease Study (AREDS) 
illustrating eyes in AMD Categories 2 and 3. One left eye in Category 2 shows 
nonextensive intermediate drusen with no druse being 125 µm or greater in diameter 
(panel A). One left eye in Category 3 depicts the lower limit of the category, having 1 
large druse greater that 125µm in diameter  (panel B). Another left eye shows many large 
drusen scatted throughout the macula totaling at least 1-disc area (Panel C). Image from 
AREDS Report No. 8, 2001. 
 
Treatment 
Panretinal Photocoagulation (PRP) 
 PRP is a procedure involving the placement of laser burns in the peripheral retina, 
the thermal energy from which induces tissue coagulation (Reddy & Husain, 2018). PRP 
is used to treat conditions that cause extensive peripheral ischemia such a PDR and 
RVOs. This treatment is theorized to stop the progression of ischemic diseases by 
improving retinal oxygenation and decreasing the drive for VEGF production by the 
retina. Improved oxygenation occurs in two ways: laser burns cause retinal thinning and 
photoreceptor death. Zhu et al. (2015) investigated changes in choroidal thickness after 
 
23 
PRP using enhanced depth imaging optical coherence tomography. The mean choroidal 
thickness in the lasered areas decreased significantly at one month and three months post-
PRP (Zhu et al., 2015). The thinning makes the choriocapillaris physically closer to the 
inner layers, which can improve oxygenation by decreasing the diffusion distance. Also, 
destroying the highly metabolically active photoreceptors reduces the overall retinal 
oxygen demand (Reddy & Husain, 2018). 
 Argon laser photocoagulation can be used to ablate the area of active CNV in 
patients with nAMD (Cook et al., 2008). The Macular Photocoagulation study established 
that laser photocoagulation prevented severe loss of vision (loss of six or more lines of 
visual acuity) in extrafoveal CNV secondary to AMD (“Argon Laser Photocoagulation 
for Senile Macular Degeneration,” 1982). This randomized, controlled trial terminated 
recruitment to the intervention arm at 18 months as 60% of untreated eyes, but only 25% 
of treated eyes had severe visual loss. A 5-year follow-up study showed that 64% of 
untreated eyes developed severe visual loss compared with 46% of treated eyes (Cook et 
al., 2008). 
Intravitreal Injection 
 Intravitreal injections allow the physician to deliver medication with a higher 
likelihood of therapeutic effect at the intended target tissue, and a correspondingly lower 
risk of systemic side effects (Doshi et al., 2011). The introduction of anti-VEGF agents to 
ophthalmology practice has advanced the treatment of retinopathies (Cook et al., 2008). 
Population-based data suggests that legal AMD-related blindness has been reduced by 
50% in some countries since the introduction of VEGF antagonists (Bressler et al., 2011). 
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Although a cure remains elusive, timely treatment with anti-VEGF can help achieve the 
nAMD treatment goals of drying the affected retinas and improving visual acuity over 
long periods (Kertes et al., 2020). Several studies have demonstrated that anti‐VEGF 
antibodies inhibit VEGF mediated neovascularization and permeability in both in vitro 
and in vivo studies (Boyd et al., 2002). Therefore, there is a strong basis for the 
hypothesis that anti‐VEGF agents may be beneficial in the treatment of vascular leakage 
and macular edema (Campochiaro et al., 2008) 
 Currently, there are several available anti‐VEGF agents. Initially developed for 
use in oncology (licensed for use in colorectal cancer), bevacizumab (Avastin®, 
Genentech) has been increasingly used as an intravitreal injection to treat nAMD. 
Bevacizumab is a full-length, humanized, monoclonal antibody binding all forms of 
VEGF-A (Cook et al., 2008), and blocks the binding of VEGF to endothelial cell 
receptors (Ferrara 2006). Bevacizumab, which is not approved by the Food and Drug 
Administration (FDA) for any ocular indication, is widely used for off-label treatment of 
DME in repackaged aliquots containing 1/500th of the systemic dose used in cancer 
therapy (“Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema,” 
2015). Ranibizumab (Lucentis®, Genentech) is a recombinant humanized monoclonal 
immunoglobulin antibody fragment that binds to the receptors of biologically active 
VEGF‐A and has been licensed for the treatment of AMD and RVOs in the USA and 
Europe (Presta 1997). Aflibercept (Eylea®, Regeneron Pharmaceuticals) is a fusion 
protein composed of key extracellular domains from human VEGF receptors 1 and 2 and 
the constant region from human IgG1 (Ogura et al., 2014). The molecule functions as a 
 
25 
soluble decoy receptor, binding to multiple VEGF-A isoforms and placental growth 
factor, thereby preventing these proangiogenic ligands from binding to and activating 
endothelial VEGF receptors. 
 Both PRP and IVI have the capability of improving disease status and visual 
acuity in patients for whom they are indicated. Gross et al. (2018) compared the efficacy 
and safety of PRP to IVI ranibizumab over five years of treatment for PDR from the 
Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial. In this 
study, eyes were randomly assigned to receive intravitreous ranibizumab or PRP. DME 
could be managed with ranibizumab in either group. Individuals that had bilateral PDR 
would have each eye randomized to a different treatment. The mean (SD) change in 
visual acuity letter score was 3.1 (14.3) and 3.0 (10.5) letters for the ranibizumab and 
PRP groups, respectively (p-value= .68) (Gross et al., 2018). The mean visual acuity in 
both groups was 20/25, as measured at the five-year time point. Worth noting is that 
vision impairing DME developed in 27 and 53 eyes in the ranibizumab and PRP group, 
respectively (hazard ratio: 0.4). The researchers concluded that visual acuity in most eyes 
in the study that completed follow-up was excellent and similar in both groups at five 
years post-randomization. Ultimately, patient-specific factors, including anticipated visit 
compliance, cost, and frequency of visits, should be considered when choosing treatment 
for patients with PDR (Gross et al., 2018).  
Loss to Follow-Up 
 Visit adherence has been shown to play a significant role in patient health 
outcomes (Ramakrishnan et al., 2020). The effect of missing visits on visual acuity and 
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disease state in patients with RVO, DR, or AMD can be significant. Despite substantial 
progress in the treatment of retinopathies, gaps and challenges persist, including the cost 
and inconvenience associated with frequent treatments. Varano et al. (2015) conducted a 
cross-sectional survey in nine countries to evaluate the current management of nAMD 
and to identify barriers to treatment from a patient and caregiver perspective. A total of 
910 patients with nAMD and 890 caretakers completed the questionnaire. A majority of 
patients (82.1%) received support from a caregiver. The relation of the caregiver was 
either a child or grandchild of the patient (47.3%), partner (23.3%), or friend (13.7%) 
with the remaining single-digit percentages being sibling (6.0%) or volunteer (3.3%). 
Only 6.5% were professional (paid) caregivers. Additionally, the majority of caregivers 
(63%) also lived with the patient. As is often the case with treatment adherence, patients 
with bilateral nAMD were more likely to attend more frequently compared to patients 
with unilateral nAMD, 33.4% versus 25.4%, respectively (Varano et al., 2015). Most 
patients (65.4%) and caregivers (77.0%) in their survey reported several obstacles in 
managing nAMD (Figure 9). For both patients and caregivers, the main barrier was the 





Figure 9. Obstacles to nAMD Management and Treatment 
Obstacles, as reported from a patient (n=910) and caregiver (n=890) perspective (panel 
A), including patient-specific reasons for difficulty attending every appointment (panel 
B). Image from Varano et al., 2015. 
 
 To overcome these barriers mentioned above, retina specialists have developed 
alternative regimens in which patients receive injections at extended fixed intervals as 
needed based on disease activity or by the treat-and extend (T&E) strategy. The goals of 
these approaches are to minimize exudative disease active activity, maintain or improve 
visual activity, and reduce the number of injections needed (Kertes et al., 2020). In 
general, the T&E approach includes a loading phase of monthly treatment, followed by a 
maintenance phase. After the loading phase, the interval between injections is 
progressively shortened or lengthened depending on the presence or absence of disease 
activity (Agarwal et al., 2015). The Canadian Treat-and Extend Analysis Trial with 
Ranibizumab (CANTREAT) sought to compare the efficacy of the T&E regimen versus a 
monthly dosing regimen. The trial was a prospective, randomized, open-label, 
multicenter, noninferiority study that recruited treatment-naïve patients with CNV 
secondary to AMD (Kertes et al., 2019). Patients with nAMD were randomized 1:1 to 
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receive intravitreal ranibizumab at a dose of 0.5 mg in either T&E or monthly dosing 
regimens. The primary outcome of the clinical trial was the mean change in best-
corrected visual acuity (BCVA) from baseline to month 12. Kertes et al. (2019) found 
that the primary outcome of noninferiority regarding visual acuity was met with a mean 
BCVA improvement of 8.4 letters in the T&E group and 6.0 letters in the monthly group. 
In addition to an improvement in vision, the clinical trial showed significantly fewer 
injections were needed during the 12-month study period. The T&E arm had 9.4 
injections on average compared to 11.8 injections for the monthly dosing arm (Kertes et 
al., 2019). These findings suggest that change in vision from baseline is not inferior with 
T&E compared to a monthly regimen, achieving clinically meaningful improvements in 
BCVA despite fewer injections and visits. Requiring fewer injections could help patients 
overcome barriers related to attending every appointment and prevent loss to follow-up 
(LTFU). 
 Understanding the risk factors associated with LTFU could help providers 
identify patients at high risk of being LTFU. Boulanger-Scemama et al. (2015) 
retrospectively analyzed adherence to follow-up over five years in patients treated with 
ranibizumab for nAMD. Of the 201 patients included in the analysis, the rate of LTFU 
over the five years was 57%. Fifty-eight patients LTFU were able to be contacted and 
responded to a questionnaire. The main reasons reported by patients for follow-up 
discontinuation were a long distance from home to the hospital (51.7%), subjective 
dissatisfaction with the benefits of IVI (34.5%), and the excessive burden of periodic 
follow-up visits (24.1%) (Boulanger-Scemama et al., 2015). Additionally, high age and 
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poor BCVA at baseline were significantly associated with poor adherence to follow-up 
seen in this study. 
 Closer to the question asked in this thesis, Obeid et al. (2018) investigated the 
percentage of patients with nAMD that were LTFU after receiving intravitreal anti-
VEGF. This research group specifically tried to identify patients that started treatment but 
were lost before completing their scheduled treatment. This cohort study of data from 
9,007 patients reported that the percentage of patients LTFU after an anti-VEGF injection 
was greater than 20% when choosing at least 12 months as the threshold with no 
subsequent follow-up visit (Obeid et al., 2018). Odds of LTFU were greater among 
patients greater than 80 years of age (OR:1.58), having an adjusted gross income below 
$50,000 (OR: 1.52), and living more than 20 miles from the clinic (OR:1.33). Similar to 
the results from prior studies, the odds of LTFU were greater among patients who 
received unilateral injections (OR:1.44) than those among patients who received bilateral 
injections. 
 These studies indicate that research into the risk factors associated with LTFU 
should be studied to understand the barriers that exist in the delivery of care. Producing 
data specific to a regional area could influence policy to overcome obstacles related to 





 The purpose of this study was to determine LTFU rates among a retrospective 
cohort of patients with RVO, AMD, and DR who were scheduled for an IVI of anti-
VEGF from an urban, hospital-based, single-site retina practice. We also aimed to 
investigate potential risk factors associated with LTFU and to model the relationship 
statistically. We hypothesized that being younger than 65, older than 85 years of age, or 
having Medicaid would negatively impact treatment adherence. Lastly, we hypothesized 
that being diagnosed with only one eye disease would negatively impact treatment 







 All patients previously diagnosed with RVO, DR, and AMD who were scheduled 
for an IVI with anti-VEGF from September 1, 2009, to September 30, 2019, were 
identified from the electronic medical record database of the Ophthalmology Department 
Retina Service of the Beth Israel Deaconess Medical Center (BIDMC) using International 
Classification of Diseases, Ninth Revision billing codes. BIDMC is an urban hospital 
located in Boston, MA. Intervals between each IVI and the next subsequent follow-up 
visit were measured for each patient. For patients with multiple injections, the interval of 
the longest duration was selected to assess for LTFU. 
Definition of LTFU 
 Loss to follow-up was defined as at least one interval exceeding 180 days for any 
patient. The duration threshold was chosen to account for the variation in the physician’s 
treatment regimen, provide adequate time for patients who might have missed their 
appointment for a variety of health or personal reasons to return, and compensate for 
patients who might travel to other states or countries for a portion of the year. If a patient 
missed an appointment without prior cancellation, it would be recorded in the electronic 
medical record as Did Not Keep (DNK). Generally, a patient will be scheduled for a 
single injection per month for three of four months. Following this series of injections, a 
patient will be scheduled for a follow-up examination to assess his or her response to 
treatment. If a patient receives a DNK for one of the injection appointments and is not 
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seen again for at least 180 days, we can reasonably conclude that at least one, if not all, 
injection appointments and follow-up examinations were missed. 
Statistical Analysis 
 Statistical analyses were performed using R, version 3.6.3 (R Foundation for 
Statistical Computing, Vienna, Austria) and SAS, version 9.4 (SAS Institute Inc., Cary, 
NC, USA). The number and percentage of patients that were LTFU were determined. The 
LTFU rates were stratified by patient characteristics and assessed for differences using 
appropriate statistical tests. For continuous variables, means were compared using an 
independent samples t-test at a two-sided 0.05 level of significance. Before the test, 
Levene’s test was used to assess equality of variance between groups at a two-sided 0.10 
level of significance. If the variances were considered significantly different, a Welch 
adjustment was to be applied to the comparison of means. The difference in LTFU rates 
between categorical risk factors was assessed using a chi-square test (χ2), or Fisher’s 
exact test, when appropriate. The literature states that when more than 20% of cells have 
expected frequencies of < 5, Fisher’s exact test should be used because applying the χ2 
approximation method is inadequate (Kim, 2017). Potential risk factors for LTFU were 
then evaluated using a univariate logistic regression. Risk factors with P<.1 on univariate 
regression were used in a multivariate logistic regression model to adjust for potential 
confounders. Two-tailed p-values were used in the analyses. 




 A total of 698 patients were identified as being scheduled for an IVI of anti-
VEGF for the treatment of RVO, DR, and AMD between the dates of September 2009 
and September 2019. Among the 698 patients, 577 (82.7%) kept their appointments, and 
121 (17.3%) DNK their appointments and were considered LTFU by the 180-day 
definition set in this study. Median (interquartile range [IQR]) patient age and mean (SD) 
patient age were 70 years (IQR, 62-81 years) and 70.23 (14.2) years, respectively. The 
baseline characteristics of patients in each group are summarized in Table 2. 
Risk Factors for LTFU 
 When age was considered as a continuous variable, the mean (SD) age of the 
LTFU group was 68.8 (15.4) and was 70.5 (14.0 ) for the not LTFU group. Levene’s test 
indicated no significant difference between groups with respect to variance (p=.19). The 
difference in mean age (95% CI) was -1.67 (-4.66, 1.32) with an associated p-value 
of .27. Based on the t-statistic of -1.10, a confidence interval that crosses the null value of 
0, and p-value larger than .05, there is no evidence of a significant difference in age 
between the not LTFU and LTFU groups. This conclusion is also supported visually by 





Figure 10. Distribution of Age for LTFU and Not LTFU Groups 
The top panel and middle panels are histograms that show the distribution of ages in the 
LTFU (DNK) and not LTFU (KEPT) groups, respectively. The blue and red overlaid 
lines are the normal and kernel density estimations, respectively. The bottom panel is a 
box-and-whisker plot of the age distribution. DNK= did not keep.  
 
 When age was considered as a categorical variable it was observed that the 
proportion of patients LTFU tended to decrease with increasing age and that the youngest 
age category had the highest proportion of LTFU. 17.2% of patients in the not LTFU 
group that were less than 64, 9.5% were 65-69, 8.7% were 70-74, 6.6% were 75-79, 8.0% 
were 80-84, 5.9% were 85-89, and 4.0% were greater than 90 years of age. In the LTFU 
group, 36.4% were less than 64, 14.9% were 65-69, 10.7% were 70-74, 9.1% were 75-79, 
12.4% were 80-84%, 6.6% were 85-89, and 9.1% were greater than 90 years of age. A χ2 
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test of independence was performed, and the test statistic was 4.87, with six degrees of 
freedom, and a p-value of .56.  
Table 2. Characteristics of Patients with DR, RVO, and AMD Who Received anti-
VEGF Injections by Follow-up Status 
Percentages for each category may not sum to 100% due to missing data. Superscripts for 
a, b, and c correspond to p-values obtained from independent samples t-test, chi-square 
test, and Fisher’s exact test, respectively. SD= standard deviation. DR= diabetic 
retinopathy. RVO= retinal-vein occlusion, AMD= age-related macular degeneration. 
LTFU= loss to follow-up 
 Follow-up Status  























































































 There was no difference in the proportion of men and women that were LTFU 
compared to not LTFU. Female patients made up 54.7% in the LTFU group and 53.54% 
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in the not LTFU group (P=.95, by χ2 test). Categorization by insurance type showed that 
70.8% of the patients keeping their appointment were on Medicare, whereas of those that 
DNK, only 50.4 % were on Medicare. Additionally, patients with Medicaid were a 
greater proportion in the DNK group (14.0%) compared to the kept appointment group 
(8.6%). Insurance type was tested with Fisher’s exact test because of the small observed 
frequencies in the self-pay and community plan categories. A test statistic of 7.70, with 
four degrees of freedom, and a p-value of .09 was observed. The proportion of each 
diagnosis differed between the two groups. With DR, there was a greater proportion of 
patients with the DR diagnosis in the LTFU group (56.2%) than in the not LTFU group 
(47.9) (P = .09, by χ2 test). RVO was almost equally seen in both groups with 23.2% in 
the not LTFU group and 20.8% in the LTFU group (P = .59, by χ2 test). There was a 
statistically significant difference in the proportion of AMD patients in each group. The 
not LTFU group had 34.7% and the LTFU group had 23.3% (P = .02, by χ2 test). 12.0% 
of patients in the kept appointment group had two or more diagnoses compared to 6.7% 
in the LTFU group (P = .10, by χ2 test). 
 Univariate logistic regression showed that having the diagnosis of AMD appears 
to be protective as it decreases the odds of being LTFU (OR=.57, P=.02). Conversely, a 
patient with Medicaid compared to a patient with Medicare, increased the odds of being 
LTFU (OR=2.31, P=.01). No other variables were found to be significantly associated 
with LTFU in the univariate model (Table 3).  
 Diagnoses of DR, AMD, having two or more diagnoses, and having Medicaid all 
met the P<0.1 threshold set a priori to be included in the multivariate model. Multivariate 
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analysis showed that a patient with Medicaid remained independently associated with 
LTFU, after adjusting for diagnosis. The other variables were not significant but showed 
trends. Patients with DR had 60% greater odds of LTFU when compared to patients 
without DR (P=.12). Patients with AMD had 19% decreased odds of being LTFU (p=.53) 
and having two or more diagnoses decreased the odds of LTFU by 51% (P=.12). 
Table 3. Univariate and Multivariate Regressions of the Potential Risk Factors 
Associated with Loss to Follow-Up among patients with AMD, DR, and RVO 
In patients that were LTFU for an injection of anti-VEGF. SD= standard deviation. DR= 
diabetic retinopathy. RVO= retinal-vein occlusion, AMD= age-related macular 
degeneration. LTFU= loss to follow-up. OR=odds ratio. OR>1 indicates increased odds 
of LTFU. Three dashes indicate not included in multivariate analysis. *Multivariate 
analysis adjusted for insurance type and diagnosis.  
 Univariate Model Multivariate Model* 



















































































































 Our study analyzed LTFU rates for patients with AMD, RVO, and DR scheduled 
for an injection of anti-VEGF. We hypothesized that being younger than 65, older than 
85 years of age, or having Medicaid would negatively impact treatment adherence. We 
also hypothesized that being diagnosed with only one eye disease would negatively 
impact treatment adherence, but that being diagnosed with more than one eye disease 
would increase treatment adherence. We found the rate of LTFU in this retrospective 
cohort to be 17.3% when using the 180-day definition of LTFU. This rate of LTFU is 
similar to the findings of earlier studies that assessed non-compliance with follow-up and 
LTFU among patients receiving IVI anti-VEGF. One study observed a rate of LTFU in 
their cohort of 22.2% (Obeid et al., 2018), and another observed 25.3% (Gao et al., 
2019). The findings from these previously published studies and this study suggest a 
sizable portion of patients who potentially do not start or correctly complete their 
physician-recommended treatment. 
 This study diverged from existing research that examined rates of LTFU strictly 
in patients of one diagnosis. Gao et al. (2018) determined the rate of LTFU in patients 
with NPDR who had DME and were receiving IVI anti-VEGF. Obeid et al. (2018) 
focused their efforts on patients with PDR who were LTFU after PRP or anti-VEGF 
injections. Lastly, another paper by Obeid et al. (2018) examined rates of LTFU in a 
cohort of nAMD patients. This study, however, aimed to investigate differential rates of 




 We found that a patient having the diagnosis of AMD was associated with a lower 
risk of being LTFU (odds ratio [OR], 0.57; 95% CI, 0.36-0.92; P=.02). There was a trend 
toward higher risk of LTFU in patients with DR in this cohort, but it was found to be 
insignificant (OR, 1.42; 95% CI, 0.94-2.15; P=.09). Perhaps with a larger sample size, it 
could be determined if DR patients in this regional area are at higher risk of being LTFU. 
Finally, we did not detect an association between the diagnosis of RVO and being LTFU 
(OR, 0.87; 95% CI, 0.53-1.44; P=.59). 
 Prior studies have delineated between bilateral and unilateral eye disease and 
found that bilateral eye disease was significantly associated with lower rates of LTFU 
(Obeid et al., 2019). Laterality data was not available in this analysis. Instead, a patient 
with more than one diagnosis was explored as a proxy variable for laterality, specifically, 
bilateral eye disease. The patients in our analysis leaned toward having a lower risk of 
being LTFU (OR, 0.53; 95% CI, 0.24-1.15; P=.10). Realistically, this result could either 
be indicative of bilateral involvement or poorer unilateral eye disease that greatly affected 
visual acuity in that eye. The chi-square test was underpowered to detect a noticeable 
difference between the two groups because of the low observed frequencies for more than 
one diagnosis. More research will need to be done to see how well multiple diagnoses can 
replicate the lower risk of LTFU as seen with bilateral eye disease. 
 A notable finding in our study was the disparity in LTFU rates among patients of 
different insurance coverage types. The odds of LTFU was higher among patients with 
Medicaid insurance (OR, 2.31; 95% CI, 1.22-4.33; P=.01), compared to patients with 
Medicare insurance. Insurance type is correlated with patient demographics and could be 
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used in further studies if other patient characteristics cannot be measured. For example, 
patients using Medicare will, on average, be older than patients using an employer-based 
HMO or PPO insurance. Also, patients on Medicaid will, on average, be in lower-income 
brackets than patients that have insurance through their place of employment. Other 
studies have collected income and racial data, but in the absence of that information, 
insurance coverage could prove to be an informative replacement variable. 
 Age was found to not be significantly different between the two groups with 
respect to their means. Increasing age tended to be associated with decreasing LTFU rates 
but was not significant in this analysis. The chi-square test was underpowered to detect a 
difference between the two groups at six degrees of freedom. Future studies could 
classify age into fewer categories to lower both the degrees of freedom and the critical 
value needed for a significant outcome. In the demographic table, it was seen that patients 
in the age category <64 had a high proportion of being LTFU. Potentially, future studies 
could focus their attention on the rates of LTFU in younger patients with eye disease. 
Limitations 
 The current study had several limitations inherent in LTFU research. One is the 
definition of LTFU. Patients were considered to be LTFU whether they had only one or 
multiple LTFU intervals. In other words, the definition used in this study did not allow us 
to distinguish between patients with a single LTFU episode from patients who had 
multiple LTFU episodes over the ten-year analysis period. Additionally, patients were 
considered LTFU without the knowledge if they had passed away. That could introduce a 
bias if patients that had died were mistakenly included in the analysis as being LTFU. 
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There was also missing data associated with age and diagnosis that could have skewed 
the results. No racial data was available for this analysis, which may limit the practical 
usage of this data. Finally, the results presented may not be generalizable to patients with 
AMD, DR, or RVO in other practices or regions, thus necessitating future studies to 






 Our retrospective cohort study revealed high rates of LTFU among patients with 
AMD, RVO, and DR scheduled for anti-VEGF injections at a single retina practice. We 
identified risk and protective factors associated with LTFU among this population using 
univariate and multivariate logistic regressions. Although our results may not be 
generalizable, data on LTFU in a clinical practice setting are needed to understand the 
scope of the problem so that interventions may be designed to improve outcomes. Future 
studies should explore such interventions and investigate what changes can be made to 
remove barriers to care and increase treatment adherence. Ultimately, the research data 
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